Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.
Type 1 MI, Type 2 MI, and non-ischemic myocardial injury, as this affects diagnostic coding and reimbursement.
Cystatin C is an emerging biomarker that enhances kidney function assessment accuracy, particularly in hospitalized patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback